The Profit That Wouldn't Follow the Growth
Revenue surged 67% to ₹1,437 crore, but net profit fell 7% to ₹119 crore. A massive restructuring — Comfort Click's ₹80–85 crore annual fixed cost — explains the gap. The real debate: can the company absorb that cost and still hit its 17–18% EBITDA margin target by FY28–29?
₹119 Cr
–7% YoY
~₹29 Cr
Comfort Click brands
~₹148 Cr
+26.5% YoY
On screen, Zydus delivered ₹1,437 crore in revenue and ₹119 crore in net profit. The headline is lopsided: while sales jumped 67% year-over-year, profit fell 7%. That gap — revenue booming while profit retreats — is the entire story of the quarter, and it is not a cash flow issue. It is a structural consolidation taking its toll on margins.
The Comfort Click tab
In Q4 FY26, Zydus acquired Comfort Click, a UK-based D2C health and wellness player. The company was consolidated into Zydus' P&L starting that quarter. In Q1 FY27, that consolidation is now full-quarter embedded. The tab: ₹80–85 crore in annual fixed costs (interest, depreciation, and amortization of acquired brands). Of that, roughly ₹24–30 crore flows through the P&L as amortization each quarter. That amortization is one reason reported PAT fell despite the massive revenue jump. Adjusted PAT — excluding amortization — rose 26.5% year-over-year, signalling the underlying cash generation is intact. But the amortization is real; it must be absorbed.
Consolidated net sales INR 14,370 million, 66.7% YoY growth
Verified: Revenue ₹1,437 Cr is 66.9% YoY growth
Supported
Net profit declined 7% YoY; adjusted PAT (ex-amortization) +26.5% YoY
Verified: Reported PAT ₹119 Cr (–7% YoY), adjusted ~₹148 Cr (+26.5% YoY)
Supported
EBITDA margin expansion 0.4% like-for-like basis; EBITDA growth 55.3%
Consistent with call data; margin expansion claim minimal but auditable
Supported (auditable)
Seasonal brands declined 12%, primarily softer summer rains East/North
Verified: Nycil and Glucon-D impacted by unseasonal monsoon April–May
Supported
Maintaining 17–18% EBITDA margin aspiration (long-term strategy)
Delivered OPM 16.8%, NPM 8.3%; timeline now described as 2–3 years, not near-term
Partially credible — aspiration held, timeline extended
What changed on this call
Comfort Click is now structural. ₹80–85 crore annual fixed cost embedded in the P&L; EPS accretive from Q4 FY26 onward, but margin accretion requires revenue scale. No easy de-lever if growth softens.
Domestic growth decelerated. Q1 domestic +4.6% vs. prior calls' implied double-digit trajectory. Seasonal brands down 12%; core brands (Complan, Everyuth, RiteBite) double-digit, but insufficient offset.
Margin expansion timeline extended. Aspiration to 17–18% EBITDA reiterated but now 'long-term' (2–3 years), not near-term. Prior calls' margin-expansion narrative downgraded.
Organized channel mix improved; seasonal risk acknowledged. Organized 38% (modern trade 17%, digital 21%); industry-leading. But portfolio volatility (–12% seasonal) shows diversification is incomplete.
The bull-bear ledger
Revenue growth 67% is structural (domestic +4.6%, international +24.8% like-for-like)
Premiumization working: Skin & Hair +34.5%, Food & Nutrition +16% growth
RiteBite >2× historical growth; Complan gaining despite category decline; Everyuth 5th→4th rank
Organized channel 38%, digital 21%; industry-leading mix supports margins long-term
Adjusted PAT +26.5% YoY shows underlying cash generation intact despite reported decline
Reported PAT –7% YoY despite 67% revenue growth signals 730bps margin compression
Fixed costs ₹80–85 Cr now permanent; fragile if growth slows or sentiment sours
Sequential QoQ deterioration severe: revenue –3.2%, PAT –26.6% (profit decline worse than sales)
Seasonal brands still volatile; Nycil/Glucon-D down 12%; 3-year shelf-life prolongs drag
Margin guidance credibility hit: aspiration held, but 2–3 year timeline extends inflection window
Risks, ranked by severity to a holder
Fixed-cost burden; margin inflection timing uncertain
HighComfort Click's ₹80–85 crore annual cost is now permanent overhead. If growth slows (domestic +4.6% is below trend), fixed-cost leverage inverts and margin compression accelerates. 17–18% EBITDA aspiration is 2–3 years out, not near-term.
Seasonal portfolio volatility unresolved
HighNycil/Glucon-D (East/North) down 12% this quarter; 3-year shelf-life means bad seasons prolong cash drain. Management expects monsoon recovery in Q2, but history shows seasonal brands structurally challenged. Channel inventory overhang risk remains.
Domestic growth deceleration
MediumQ1 domestic +4.6% materially below prior double-digit trajectory. Core brands growing double-digit (Complan, Everyuth, RiteBite), but offset insufficient. Premium mix helps, but core market momentum slower than guided.
Earnings quality and amortization dependency
MediumReported vs. adjusted PAT gap of ~₹29 crore creates large narrative window. Amortization (~₹24–30 crore quarterly) will persist for years. Tempts management to emphasize adjusted metrics and obscure core profitability strain.
The street's view
The stock fell 3.6% on day 1 post-result and declined 2.85% by day 3, holding the loss with no recovery pop. The market's verdict: disappointing, but not catastrophic. At ₹534.5, the stock trades 12.46% below its all-time high of ₹610.6 but sits 45.42% above its 52-week low (₹367.55). Price action sits below both the 20-day and 50-day moving averages (₹567.59 and ₹546.55) but above the 200-day (₹473.08), signalling intermediate weakness without structural breakdown. RSI at 31.5 is neutral — not oversold. Institutions aren't fleeing: FII ownership ticked up from 3.18% to 3.32%; DII held stable at ~19%; promoter remains firm at 69.64%, unchanged for three years. Volume has increased, confirming the move is not low-volume. The market is repricing from 'growth at any cost' to 'growth with profitability questions' — fair, given sequential PAT decline and margin guidance credibility hit.
1 · Q2 organic run-rate (monsoon recovery, seasonal rebound)
Is the seasonal drag truly temporary, or does it prolong into Q2? Nycil/Glucon-D (East/North) recovery timing will define whether the 12% decline was a one-quarter trough or the start of prolonged headwind. Management expects recovery 'towards the end of Q1' and into Q2; numbers will confirm or refute. Watch for QoQ PAT inflection.
2 · Comfort Click ramp velocity (U.S./Middle East expansion, unit economics)
Comfort Click like-for-like growth was +24.8% in established markets (Europe). U.S. entry (WeightWorld D2C, Walmart, noon UAE) is 'very small, early stage, growing well.' Next quarter shows whether U.S./Middle East expansion is tracking to scale or remains niche. Margin inflection case depends on this business reaching ₹500+ crore revenue over 2–3 years.
3 · RiteBite offline T2/T3 expansion and EBITDA contribution
RiteBite >2× historical growth driven heavily by quick commerce. Offline expansion into T2/T3 towns is underway with committed resources. If that scales, RiteBite becomes a meaningful profit driver and validates premiumization thesis. Watch for quick commerce saturation and general trade traction.
This quarter is a test of whether growth and profitability can coexist at Zydus Wellness. Reported numbers suggest they cannot — not yet. But the adjusted figures suggest the business remains fundamentally sound; Comfort Click is a temporary profit headwind, not a strategy error. The honest read is steady execution, not a step-change. Revenue growth is structural; margin inflection is multi-year and contingent on Comfort Click scale and domestic growth recovery. The number to track from here is the organic profit run-rate (adjusted PAT) and the pace of Comfort Click revenue ramp. If domestic growth stays below 5% and Comfort Click remains a single-digit revenue contributor, the 17–18% EBITDA margin target will remain a 3-year aspiration. The street has priced in skepticism. Execution will decide whether that view holds.
Informational and educational content only. Not investment advice.